文献速递脊柱关节炎

中轴型脊柱关节炎患者停用依奇珠单抗后再捕获与再治疗率:随机安慰剂对照撤药研究第104周结果

Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.
PubMed 文献 · Ann Rheum Dis · 2022-09-13

COAST-Y Ⅲ期扩展研究纳入155例中轴型脊柱关节炎患者,在随机撤药-再治疗期停用依奇珠单抗后复发者接受开放标签再治疗。第104周时,停用安慰剂后复发者中96%再捕获至少ASDAS低疾病活动度、71%再捕获ASDAS非活动性疾病。

要点

  • 停用依奇珠单抗后复发者接受开放标签再治疗,第104周96%再捕获ASDAS低疾病活动度、71%再捕获ASDAS非活动性疾病。
  • 安慰剂组53例中28例(53%)在第24-104周复发,再治疗后23例(82%)再捕获ASDAS低疾病活动度、19例(68%)达ASDAS非活动性疾病。
  • 持续依奇珠单抗治疗组102例中13例复发,再治疗后5例(38%)再捕获ASDAS低疾病活动度、4例(31%)达ASDAS非活动性疾病。

核心结论

  • 停用安慰剂后复发的患者接受依奇珠单抗再治疗,第104周时96%再捕获至少ASDAS低疾病活动度、71%再捕获ASDAS非活动性疾病。
  • 作者认为这可能为需要短暂中断治疗的患者提供支持。

研究设计与样本

  • COAST-Y(NCT03129100)为Ⅲ期扩展研究,包含双盲、安慰剂对照、随机撤药-再治疗期。
  • 在第16周或第20周至少一次达到缓解(ASDAS<1.3,非活动性疾病)且两次访视均<2.1(低疾病活动度)的患者,于第24周按2:1随机继续依奇珠单抗或撤药至安慰剂。
  • 随后复发者在下一次访视时转为开放标签依奇珠单抗每2周或每4周一次。
  • 进入撤药-再治疗期的155例患者中,安慰剂组53例、依奇珠单抗每4周组48例、依奇珠单抗每2周组54例;138例(89%)完成第104周。

主要发现

  • 安慰剂组53例中28例(53%)在第24-104周期间复发;其中4例(14%)在开放标签依奇珠单抗再治疗前再捕获ASDAS低疾病活动度,再治疗后23例(82%)再捕获ASDAS低疾病活动度、19例(68%)达ASDAS非活动性疾病。
  • 持续依奇珠单抗治疗组102例中13例复发;其中7/13(54%)在转为开放标签依奇珠单抗再治疗前再捕获ASDAS低疾病活动度,转换后5/13(38%)再捕获ASDAS低疾病活动度、4/13(31%)达ASDAS非活动性疾病。

关键数值与推荐

  • 缓解定义:第16周或第20周至少一次ASDAS<1.3(非活动性疾病)且两次访视均<2.1(低疾病活动度)。
  • 再捕获ASDAS低疾病活动度和非活动性疾病的的比例按复发患者汇总。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the recapture of response with open-label (OL) ixekizumab (IXE) retreatment at week 104 in patients with axial spondyloarthritis who flared after withdrawal of IXE therapy. METHODS: COAST-Y (NCT03129100) is a phase III extension study that included a double-blind, placebo-controlled, randomised withdrawal-retreatment period (RWRP). Patients who achieved remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (inactive disease, ID) at least once at week 16 or 20 and <2.1 (low disease activity, LDA) at both visits) were randomised 2:1 at week 24 to continue IXE or withdraw to placebo. Patients who subsequently flared were switched to OL IXE every 2 or 4 weeks (Q2W or Q4W) at the next visit. The proportions of patients who recaptured ASDAS LDA and ID were summarised for those who experienced flare. RESULTS: Of the 155 patients who entered the RWRP (placebo, n=53; IXE Q4W, n=48; IXE Q2W, n=54), 138 (89%) completed week 104. Of the placebo-treated patients (n=53), 28 (53%) experienced a flare during weeks 24-104; of these, 4 (14%) recaptured ASDAS LDA before retreatment with OL IXE, and 23 (82%) recaptured ASDAS LDA and 19 (68%) met ASDAS ID after retreatment. Of the continuously treated IXE patients (n=102), 13 experienced flare; 7 of 13 (54%) recaptured ASDAS LDA before switching to OL IXE retreatment, while 5 of 13 (38%) recaptured ASDAS LDA and 4 of 13 (31%) met ID after switching. CONCLUSIONS: Ninety-six per cent of patients withdrawn to placebo recaptured at least ASDAS LDA and 71% recaptured ASDAS ID with IXE retreatment at week 104. This may provide support to patients who may require a brief interruption in therapy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Landewé RBM, Poddubnyy D, Rahman P, et al. Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study. Ann Rheum Dis. 2022. PMID: 36100350. doi:10.1136/ard-2022-222731

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。